Dynavax Technologies reported $127.67M in EBIT for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Agenus AGEN:US $ -44972000 8.98M
Amgen AMGN:US $ 2176M 324M
Astrazeneca AZN:US 2.2B 673M
AstraZeneca AZN:LN 2.2B 673M
Biogen BIIB:US $ 940.9M 409.4M
Biomarin Pharmaceutical BMRN:US $ 39.15M 9.82M
Bristol Myers Squibb BMY:US $ 3197M 9M
Chimerix CMRX:US -23447000 1.32M
Dynavax Technologies DVAX:US $ 127.67M 96.2M
Gilead Sciences GILD:US $ 2029M 868M
Glaxosmithkline GSK:US 1.82B 600M
Merk MRK:US $ 5711M 652M
Minerva Neurosciences NERV:US $ -6965190 1.02M
Nektar Therapeutics NKTR:US $ -47713000 67.37M
Neurocrine Biosciences NBIX:US $ 54.7M 51.6M
Novartis NOVN:VX 3.32B 176M
Pfizer PFE:US $ 12099M 2104M
Regeneron Pharmaceuticals REGN:US $ 1306.9M 20.3M
Sarepta Therapeutics SRPT:US $ -211132000 124.25M
Tg Therapeutics TGTX:US $ -38941000 27.93M
Vertex Pharmaceuticals VRTX:US $ 1119.3M 85.9M